Discontinuation of tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia in chronic phase (CML-CP) in US clinical practice after guideline updates.

被引：0
|
作者：
Atallah, Ehab L.
Sadek, Islam
Maegawa, Rodrigo O.
Cao, Xiting
Latremouille-Viau, Dominick
Pivneva, Irina
Rossi, Carmine
Guerin, Annie
Kota, Vamsi
机构：
[1] Med Coll Wisconsin, Hematol Malignancies, Milwaukee, WI 53226 USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Anal Grp Inc, Montreal, PQ, Canada
[4] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7548
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Discontinuation of Tyrosine Kinase Inhibitor (TKI) Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in US Clinical Practice Following Updates to NCCN CML Practice Guidelines
    Atallah, Ehab
    Sadek, Islam
    Maegawa, Rodrigo
    Cao, Xiting
    Latremouille-Viau, Dominick
    Pivneva, Irina
    Rossi, Carmine
    Guerin, Annie
    Kota, Vamsi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S231 - S231
  • [2] Symptoms Following Discontinuation of Tyrosine Kinase Inhibitor (TKI) Therapy After Achieving an Adequate Response in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Ritchie, Ellen K.
    Sadek, Islam
    Pivneva, Irina
    Guerin, Annie
    Latremouille-Viau, Dominick
    Ndife, Briana
    Joseph, George J.
    Atallah, Ehab L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S221 - S222
  • [3] Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates
    Atallah, Ehab L.
    Sadek, Islam
    Maegawa, Rodrigo
    Cao, Xiting
    Latremouille-Viau, Dominick
    Pivneva, Irina
    Rossi, Carmine
    Guerin, Annie
    Kota, Vamsi
    LEUKEMIA & LYMPHOMA, 2021, 62 (07) : 1730 - 1739
  • [4] Tyrosine Kinase Inhibitor Therapy Discontinuation in Clinical Practice in Chronic Myeloid Leukemia - a US Physician Survey Conducted after Guideline Updates
    Atallah, Ehab L.
    Sadek, Islam
    Cao, Xiting
    Latremouille-Viau, Dominick
    Pivneva, Irina
    Rossi, Carmine
    Guerin, Annie
    Kota, Vamsi
    BLOOD, 2019, 134
  • [5] Tyrosine kinase inhibitor (TKI) therapy discontinuation in patients with CML in chronic phase: A US clinical practice perspective.
    Ritchie, Ellen K.
    Wolff, Johannes E.
    Latremouille-Viau, Dominick
    Guerin, Annie
    Pivneva, Irina
    Briggs, Owanate
    Joseph, George J.
    Atallah, Ehab L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Symptoms following TKI therapy discontinuation after achieving an adequate response in patients with chronic myeloid leukemia in chronic phase (CML-CP).
    Ritchie, Ellen K.
    Sadek, Islam
    Pivneva, Irina
    Guerin, Annie
    Latremouille-Viau, Dominick
    Ndife, Briana
    Joseph, George J.
    Atallah, Ehab L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Incidence of Secondary Malignancies in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Era of Tyrosine Kinase Inhibitors (TKI)
    Sasaki, Koji
    Kantarjian, Hagop M.
    O'Brien, Susan M.
    Ravandi, Farhad
    Konopleva, Marina
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Wierda, William G.
    Daver, Naval
    Ferrajoli, Alessandra
    Takahashi, Koichi
    Jain, Preetesh
    Rios, Mary B.
    Pierce, Sherry
    Jabbour, Elias J.
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [8] Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy
    Boddu, Prajwal
    Jain, Preetesh
    Borthakur, Gautam
    Verstovsek, Srdan
    Garcia-Manero, Guillermo
    Daver, Naval
    Kadia, Tapan
    Ravandi, Farhad
    Jabbour, Elias
    Cortes, Jorge
    Kantarjian, Hagop
    LEUKEMIA & LYMPHOMA, 2019, 60 (13) : 3172 - 3180
  • [9] An Observational Study of Survival in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) After 1, 3, and 5 Years of Tyrosine Kinase Inhibitor (TKI) Therapy (SIMPLICITY)
    Michallet, Mauricette
    Cortes, Jorge
    Gambacorti-Passerini, Carlo
    Hehlmann, Rudiger
    Williams, Loretta A.
    Goldberg, Stuart L.
    Davis, Catherine
    De Solda, Francesco
    Sen, Ginny P.
    Gajavelli, Srikanth
    Mauro, Michael J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S229 - S229
  • [10] Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in US Clinical Practice, with a Focus on Tyrosine Kinase Inhibitor Therapy Discontinuation
    Ritchie, Ellen K.
    Latremouille-Viau, Dominick
    Guerin, Annie
    Pivneva, Irina
    Habucky, Karen
    Ndife, Briana
    Joseph, George J.
    Atallah, Ehab
    BLOOD, 2017, 130
12345